Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 28, 2011; 17(4): 506-513
Published online Jan 28, 2011. doi: 10.3748/wjg.v17.i4.506
Published online Jan 28, 2011. doi: 10.3748/wjg.v17.i4.506
Gender (M:F) | 18:14 |
Age of CD diagnosis: median in years (range) | 58.5 (38-74) |
Age of RCDII diagnosis: median in years (range) | 64 (42-78) |
Age at the start of 2-CdA treatment: median in years (range) | 64 (45-78) |
Treatment prior to 2-CdA | |
None | 22 |
Immunosuppressive drugs | 10 |
Follow-up time: median in months (range) | 31 (4-120) |
HLA-DQ status | |
DQ2 heterozygous | 17 |
DQ2 homozygous | 12 |
DQ2 and DQ8 | 2 |
Unknown | 1 |
TCR-γ gene rearrangement | |
Monoclonal | 18 |
Polyclonal | 9 |
Unknown | 5 |
Marsh classification before 2-CdA | |
Marsh IIIA | 13 |
Marsh IIIB | 11 |
Marsh IIIC | 8 |
Intestinal aberrant IELs before 2-CdA: median in % (range) | 61 (21-96) |
Body mass index before 2-CdA: median in kg/m2 (range) | 21 (16-27) |
Albumin level before 2-CdA: median (range, reference value 35-52 g/L) | 36 (23-47) |
Haemoglobin level before 2-CdA: median in mmol/L (range) | 7.8 (6.0-9.8) |
Treatment(n) | Response (%) | Time to a 50% response rate (mo) | |||
12 mo | 24 mo | ||||
Histological response | Group I | 10 | 13 | 25 | 36 |
Group II | 22 | 20 | 58 | 24 | |
Overall | 32 | 10 | 47 | 36 (3-96) | |
Immunological1 response | Group I | 10 | 11 | 11 | > 60 |
Group II | 22 | 52 | 58 | 12 | |
Overall | 32 | 39 | 41 | 41 (2-96) | |
Clinical2 response | Group I | 10 | 67 | 67 | 6 |
Group II | 22 | 95 | 95 | 3 | |
Overall | 32 | 81 | 81 | 3 (2-72) | |
Overall response | Group I | 10 | 22 | 38 | 36 |
Group II | 22 | 28 | 43 | 30 | |
Overall | 32 | 25 | 41 | 36 |
- Citation: Tack GJ, Verbeek WH, Al-Toma A, Kuik DJ, Schreurs MW, Visser O, Mulder CJ. Evaluation of Cladribine treatment in refractory celiac disease type II. World J Gastroenterol 2011; 17(4): 506-513
- URL: https://www.wjgnet.com/1007-9327/full/v17/i4/506.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i4.506